161 related articles for article (PubMed ID: 31622602)
1. Brain-penetrant PQR620 mTOR and PQR530 PI3K/mTOR inhibitor reduce huntingtin levels in cell models of HD.
Singer E; Walter C; Fabbro D; Rageot D; Beaufils F; Wymann MP; Rischert N; Riess O; Hillmann P; Nguyen HP
Neuropharmacology; 2020 Jan; 162():107812. PubMed ID: 31622602
[TBL] [Abstract][Full Text] [Related]
2. The novel, catalytic mTORC1/2 inhibitor PQR620 and the PI3K/mTORC1/2 inhibitor PQR530 effectively cross the blood-brain barrier and increase seizure threshold in a mouse model of chronic epilepsy.
Brandt C; Hillmann P; Noack A; Römermann K; Öhler LA; Rageot D; Beaufils F; Melone A; Sele AM; Wymann MP; Fabbro D; Löscher W
Neuropharmacology; 2018 Sep; 140():107-120. PubMed ID: 30081001
[TBL] [Abstract][Full Text] [Related]
3. Selective inhibition of mTORC1/2 or PI3K/mTORC1/2 signaling does not prevent or modify epilepsy in the intrahippocampal kainate mouse model.
Gericke B; Brandt C; Theilmann W; Welzel L; Schidlitzki A; Twele F; Kaczmarek E; Anjum M; Hillmann P; Löscher W
Neuropharmacology; 2020 Jan; 162():107817. PubMed ID: 31654704
[TBL] [Abstract][Full Text] [Related]
4. Discovery and Preclinical Characterization of 5-[4,6-Bis({3-oxa-8-azabicyclo[3.2.1]octan-8-yl})-1,3,5-triazin-2-yl]-4-(difluoromethyl)pyridin-2-amine (PQR620), a Highly Potent and Selective mTORC1/2 Inhibitor for Cancer and Neurological Disorders.
Rageot D; Bohnacker T; Melone A; Langlois JB; Borsari C; Hillmann P; Sele AM; Beaufils F; Zvelebil M; Hebeisen P; Löscher W; Burke J; Fabbro D; Wymann MP
J Med Chem; 2018 Nov; 61(22):10084-10105. PubMed ID: 30359003
[TBL] [Abstract][Full Text] [Related]
5. Modulating FKBP5/FKBP51 and autophagy lowers HTT (huntingtin) levels.
Bailus BJ; Scheeler SM; Simons J; Sanchez MA; Tshilenge KT; Creus-Muncunill J; Naphade S; Lopez-Ramirez A; Zhang N; Lakshika Madushani K; Moroz S; Loureiro A; Schreiber KH; Hausch F; Kennedy BK; Ehrlich ME; Ellerby LM
Autophagy; 2021 Dec; 17(12):4119-4140. PubMed ID: 34024231
[TBL] [Abstract][Full Text] [Related]
6. Novel brain permeant mTORC1/2 inhibitors are as efficacious as rapamycin or everolimus in mouse models of acquired partial epilepsy and tuberous sclerosis complex.
Theilmann W; Gericke B; Schidlitzki A; Muneeb Anjum SM; Borsdorf S; Harries T; Roberds SL; Aguiar DJ; Brunner D; Leiser SC; Song D; Fabbro D; Hillmann P; Wymann MP; Löscher W
Neuropharmacology; 2020 Dec; 180():108297. PubMed ID: 32890589
[TBL] [Abstract][Full Text] [Related]
7. Huntingtin promotes mTORC1 signaling in the pathogenesis of Huntington's disease.
Pryor WM; Biagioli M; Shahani N; Swarnkar S; Huang WC; Page DT; MacDonald ME; Subramaniam S
Sci Signal; 2014 Oct; 7(349):ra103. PubMed ID: 25351248
[TBL] [Abstract][Full Text] [Related]
8. (
Rageot D; Bohnacker T; Keles E; McPhail JA; Hoffmann RM; Melone A; Borsari C; Sriramaratnam R; Sele AM; Beaufils F; Hebeisen P; Fabbro D; Hillmann P; Burke JE; Wymann MP
J Med Chem; 2019 Jul; 62(13):6241-6261. PubMed ID: 31244112
[TBL] [Abstract][Full Text] [Related]
9. HIPK3 modulates autophagy and HTT protein levels in neuronal and mouse models of Huntington disease.
Fu Y; Sun X; Lu B
Autophagy; 2018; 14(1):169-170. PubMed ID: 29130397
[TBL] [Abstract][Full Text] [Related]
10. Atg4b-dependent autophagic flux alleviates Huntington's disease progression.
Proenca CC; Stoehr N; Bernhard M; Seger S; Genoud C; Roscic A; Paganetti P; Liu S; Murphy LO; Kuhn R; Bouwmeester T; Galimberti I
PLoS One; 2013; 8(7):e68357. PubMed ID: 23861892
[TBL] [Abstract][Full Text] [Related]
11. Mutant Huntingtin Inhibits αB-Crystallin Expression and Impairs Exosome Secretion from Astrocytes.
Hong Y; Zhao T; Li XJ; Li S
J Neurosci; 2017 Sep; 37(39):9550-9563. PubMed ID: 28893927
[TBL] [Abstract][Full Text] [Related]
12. Deletion of SUMO1 attenuates behavioral and anatomical deficits by regulating autophagic activities in Huntington disease.
Ramírez-Jarquín UN; Sharma M; Zhou W; Shahani N; Subramaniam S
Proc Natl Acad Sci U S A; 2022 Feb; 119(5):. PubMed ID: 35086928
[TBL] [Abstract][Full Text] [Related]
13. Gedunin Degrades Aggregates of Mutant Huntingtin Protein and Intranuclear Inclusions via the Proteasomal Pathway in Neurons and Fibroblasts from Patients with Huntington's Disease.
Yang W; Xie J; Qiang Q; Li L; Lin X; Ren Y; Ren W; Liu Q; Zhou G; Wei W; Saiyin H; Ma L
Neurosci Bull; 2019 Dec; 35(6):1024-1034. PubMed ID: 31432317
[TBL] [Abstract][Full Text] [Related]
14. Effects of Exogenous NUB1 Expression in the Striatum of HDQ175/Q7 Mice.
Vodicka P; Chase K; Iuliano M; Valentine DT; Sapp E; Lu B; Kegel-Gleason KB; Sena-Esteves M; Aronin N; DiFiglia M
J Huntingtons Dis; 2016 Jun; 5(2):163-74. PubMed ID: 27314618
[TBL] [Abstract][Full Text] [Related]
15. Modulation of mTOR and CREB pathways following mGluR5 blockade contribute to improved Huntington's pathology in zQ175 mice.
Abd-Elrahman KS; Ferguson SSG
Mol Brain; 2019 Apr; 12(1):35. PubMed ID: 30961637
[TBL] [Abstract][Full Text] [Related]
16. Activation of AMPK-induced autophagy ameliorates Huntington disease pathology in vitro.
Walter C; Clemens LE; Müller AJ; Fallier-Becker P; Proikas-Cezanne T; Riess O; Metzger S; Nguyen HP
Neuropharmacology; 2016 Sep; 108():24-38. PubMed ID: 27133377
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of GSK-3 ameliorates the pathogenesis of Huntington's disease.
Rippin I; Bonder K; Joseph S; Sarsor A; Vaks L; Eldar-Finkelman H
Neurobiol Dis; 2021 Jul; 154():105336. PubMed ID: 33753290
[TBL] [Abstract][Full Text] [Related]
18. Gossypol, a novel modulator of VCP, induces autophagic degradation of mutant huntingtin by promoting the formation of VCP/p97-LC3-mHTT complex.
Li XJ; Zhang YY; Fu YH; Zhang H; Li HX; Li QF; Li HL; Tan RK; Jiang CX; Jiang W; Li ZX; Luo C; Lu BX; Dang YJ
Acta Pharmacol Sin; 2021 Oct; 42(10):1556-1566. PubMed ID: 33495516
[TBL] [Abstract][Full Text] [Related]
19. Structure and ligand-based design of mTOR and PI3-kinase inhibitors leading to the clinical candidates VS-5584 (SB2343) and SB2602.
Poulsen A; Nagaraj H; Lee A; Blanchard S; Soh CK; Chen D; Wang H; Hart S; Goh KC; Dymock B; Williams M
J Chem Inf Model; 2014 Nov; 54(11):3238-50. PubMed ID: 25317974
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of p38 Mitogen-Activated Protein Kinase Ameliorates HAP40 Depletion-Induced Toxicity and Proteasomal Defect in Huntington's Disease Model.
Huang ZN; Chen JM; Huang LC; Fang YH; Her LS
Mol Neurobiol; 2021 Jun; 58(6):2704-2723. PubMed ID: 33492644
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
